The Latest Cardiac and Vascular News
VANCOUVER and MINNEAPOLIS, May 06, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), today reported financial results for the first quarter ended March 31, 2021. First Quarter Highlights Generated revenue of $451,794 in the quarter as Neovasc Reducer™ implants rebounded after being suppressed for much of 2020 […]
Secondary Analysis from GALACTIC-HF to be Presented in Late Breaking Clinical Trial Session at ACC.21 Company Plans to Submit NDA for Omecamtiv Mecarbil following Recent Meeting with FDA Results from REDWOOD-HCM Expected Mid-Year; Open Label Extension Study and Phase 3 Clinical Trial Planning Underway SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) […]
Conference Call and Webcast at 5:00 pm Eastern Time THE WOODLANDS, Texas, May 06, 2021 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2021 and provided an update on key milestones. “We continue to enroll patients in our two proof-of-concept Phase […]
Conference call begins today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J. , May 06, 2021 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, provides a corporate update and reports financial […]
-Xenter’s Expanding Team of Industry Leaders Poised to Advance Device/Data/Drug Technologies for Interventional Medicine, Pharmaceutical Advancements and Digital Health- SALT LAKE CITY–(BUSINESS WIRE)–Xenter, Inc. (XenterMD.com), the world’s first start-up Device-Data-Drug healthcare technologies company, today announced the appointment of four additional industry leaders to its Board of Directors and the closing of […]
– PULSAR Phase 2 trial results published in New England Journal of Medicine – – Updates from the PULSAR and SPECTRA Phase 2 trials of sotatercept in patients with pulmonary arterial hypertension (PAH) to be presented at the American Thoracic Society (ATS) 2021 International Conference on May 19, 2021 – […]
The Board of Directors warmly thanks Dr. Philippe Pouletty, Managing Director of Truffle Capital, for his exceptional contribution to the development of the CARMAT project, and proposes the appointment of three new directors, Florent Battistella, David Coti and John B. Hernandez. CARMAT (FR0010907956, ALCAR), the designer and developer of the […]
Revenue of $28.7 million, up 133% year over year Operating loss of $(2.9) million, a 52% improvement year over year Adjusted EBITDA of $1.9 million, achieving consecutive quarterly positive Adjusted EBITDA Record quarterly cash flow from operations of $6.4 million, compared to $(3.1) million in Q1 2020 Jonathan Mayhew joins […]
– Second fiscal quarter revenues of $4.9 billion grew 15.4% on a reported basis. On a currency-neutral basis, revenues increased 12.2%. – BD’s COVID-19 testing sales were $480 million, including BD Veritor™ Plus System revenues of $290 million. – BD’s core growth led by strong growth in Medication Delivery Solutions […]
WESTMINSTER, Colo., May 05, 2021 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that Christopher Graybill, Ph.D., has joined ARCA as Vice President, Clinical Development. Dr. Michael Bristow, ARCA’s President and Chief Executive Officer, […]
